BMO Capital analyst Evan Seigerman has maintained their bullish stance on PFE stock, giving a Buy rating yesterday.
Evan Seigerman has given his Buy rating due to a combination of factors that suggest Pfizer is well-positioned for future growth. The company’s recent financial performance, particularly its ability to outperform expectations on cost savings, indicates a strong operational efficiency that could lead to improved profitability. Additionally, Pfizer’s management has demonstrated a commitment to strategic capital allocation and maintaining its dividend, which signals confidence in its financial stability and future prospects.
Moreover, the company’s proactive approach to navigating the current political and economic landscape, including potential implications of tariffs and changes in healthcare policy, positions it favorably compared to its peers. The analyst also highlights Pfizer’s undervaluation relative to other U.S. BioPharma companies, with its potential for top-line growth and margin expansion being underappreciated. These factors, combined with transformative acquisitions leveraging COVID cash, enhance Pfizer’s pipeline and support the Buy rating.
In another report released yesterday, Jefferies also maintained a Buy rating on the stock with a $32.00 price target.
Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is neutral on the stock.